General
Preferred name
BLONANSERIN
Synonyms
AD-5423 ()
DSP-5423 ()
P&D ID
PD008998
CAS
132810-10-7
Tags
natural product
drug
available
Approved by
PMDA
First approval
2008
Drug indication
Schizophrenia
Drug Status
investigational
approved
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Blonanserin is an atypical antipsychotic. (GtoPdb)
Compound Sets
21
AdooQ Bioactive Compound Library
A11824
Axon Medchem Screening Library
2353
Cayman Chemical Bioactives
16480
ChEMBL Drugs
CHEMBL178803
Concise Guide to Pharmacology 2017/18
7670
Concise Guide to Pharmacology 2019/20
7670
Concise Guide to Pharmacology 2021/22
7670
Concise Guide to Pharmacology 2023/24
7670
Drug Repurposing Hub
DrugBank
DB09223
DrugCentral
388
DrugCentral Approved Drugs
388
DrugMAP
DM36C17
DrugMatrix
Guide to Pharmacology
7670
Ki Database
AD-5423
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL178803
MedChem Express Bioactive Compound Library
HY-13575
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
T1180
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
367.24
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
4
Aromatic Ring Count
2
cLogP
4.69
TPSA
19.37
Fraction CSP3
0.52
Chiral centers
0.0
Largest ring
8.0
QED
0.78
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Target
5-HT2
D2
DRD2, HTR2A
Antipsychotic
5-HT Receptor
Adrenergic Receptor
Dopamine Receptor
Sigma Receptor
MOA
dopamine receptor antagonist, serotonin receptor antagonist
Indication
schizophrenia
Source data